Rahoton #WHO na baya-bayan nan kan cutar tarin fuka ya bayyana gaskiya mai karfi: An gano sabbin masu dauke da cutar tarin fuka miliyan 8.2 a shekarar 2023 - mafi girma tun lokacin da aka fara sa ido a duniya a shekarar 1995. Wannan karuwar daga miliyan 7.5 a shekarar 2022 ta dawo da cutar tarin fuka a matsayin cutar da ta fi kamari a duniya.babban mai kashe ƙwayoyin cuta, wanda ya zarce COVID-19.
Duk da haka, wani mawuyacin hali ya fi shafar wannan farfadowa:Juriyar Magungunan Ƙwayoyin Cuta (AMR)WHO ta yi hasashen cewa nan da shekarar 2050, AMR za ta iya da'awarhar zuwa rayuka miliyan 10 a kowace shekaraa duk duniya, inda tarin fuka mai jure wa magani (DR-TB) ke zama babban abin da ke haifar da cutar. A shekarar 2019 kawai, AMR ta kashe mutane miliyan 1.3 kai tsaye—wuce cutar HIV/AIDS da malaria gaba ɗaya- kuma yanzu haka shinena uku a jerin abubuwan da ke haifar da mace-mace a duniyaBa tare da shiga tsakani ba, yawan mace-macen da ake samu daga AMR na iya kaiwa gaMiliyan 39 nan da shekarar 2050, tare da asarar tattalin arziki mafi girmadala tiriliyan 100.
Dalilin da Ya Sa Ba A Iya Tattaunawa Kan Ganewar Ganowa Kan Lokaci Ba
Maganin tarin fuka ya dogara ne akan gano da wuri da kuma daidaita magunguna. Duk da haka, amfani da magungunan rigakafi ba bisa ka'ida ba ya hanzarta kamuwa da tarin fuka mai jure magunguna da yawa (MDR-TB), yana mai da cututtukan da za a iya magancewa zuwa barazanar kisa. Abin da ke da ban tsoro:
Tarin fuka mai jure wa magunguna ya kai kashi 1/3 na mace-macen AMR a duniya.
Tsufa na fuskantar karuwar mace-macen AMR(sama da kashi 80% tun daga shekarar 1990 a tsakanin tsofaffi).
Sauyin yanayi na iya faruwaYaɗuwar AMR ta ƙara ta'azzara da kashi 2.4% nan da shekarar 2050, wanda hakan ke shafar yankunan da ke da ƙarancin kuɗi.
WHO ta yi kira da a gaggauta samar da sabbin dabaru a cikin binciken gaggawa don yaki da amfani da miyagun kwayoyi da kuma cike gibin magani
Kit ɗin Tarin Fuka Mai Tabbatacce na CE-Certified Triple TB Kit na Macro & Micro-Test: Kayan Aikin Daidaitawa don Zamanin AMR
Maganinmu ya yi daidai da dabarun rage AMR na WHO ta hanyar ba da damargano kamuwa da cutar tarin fuka a lokaci guda + rifampicin (RIF) + juriyar isoniazid (INH)—muhimmi ne wajen rage CUTAR DR-TB.
Muhimman Abubuwa:
Sauri & DaidaitoSakamakon: A cikin awanni 2-2.5 tare da fassarar atomatik (ana buƙatar ƙaramin horo).
Manyan Manufofi:TB: IS6110 kwayar halitta
juriyar RIF: rpoB (507~533)
juriyar INH: InhA, AhpC, katG 315
Babban Jin Daɗi: Yana gano ƙwayoyin cuta 10/mL (TB) da kuma ƙwayoyin cuta 150–200/mL don alamun juriya.
Mai bin ka'idojin WHO: Ya cika ƙa'idodi don kula da cutar tarin fuka ta DR-TB.
Dacewar Faɗi: Yana aiki da manyan tsarin PCR (misali, Bio-Rad CFX96, SLAN-96P/S).
Dalilin da Yasa Wannan Yake Da Muhimmanci:
Gano kwayoyin halittar da ke da juriya cikin sauri yana hana amfani da maganin rigakafi yadda ya kamata, yana rage yaɗuwar cutar,
Kira zuwa Aiki
Haɗuwar sake bullar tarin fuka da kuma AMR yana buƙatar kayan aiki waɗanda suka haɗu da sauri daidai. Kayan aikinmu suna cike wannan gibin—tabbatar da cewa magani ya fara daidai, a karon farko.
Ƙara koyo:
https://www.mmtest.com/mycobacterium-tuberculosis-nucleic-acid-and-rifampicin%ef%bc%8cisonazid-resistance-product/
Tuntuɓi:marketing@mmtest.com
#IVD #PCR #AMRCrisis #Resistance Drug #TB #ENDTB #MDRTB #Diagnostics #Lafiya ta Duniya #WHO #MacroMicroTest
Lokacin Saƙo: Nuwamba-25-2025